Pediatric Clinics of North America - CIPERJ

392 ROBERTSON et al
[46] Nesbitt IM, Goodeve AC, Guilliatt AM, et al. Characterisation of type 2N von Willebrand
disease using phenotypic and molecular techniques. Thromb Haemost 1996;75:959–64.
[47] Castaman G, Rodeghiero F, Tosetto A, et al. Hemorrhagic symptoms and bleeding risk in
obligatory carriers of type 3 von Willebrand disease: an international, multicenter study.
J Thromb Haemost 2006;4:2164–9.
[48] Baronciani L, Cozzi G, Canciani MT, et al. Molecular defects in type 3 von Willebrand
disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 2003;30:264–70.
[49] Shelton-Inloes B, Chehab F, Mannucci P, et al. Gene deletions correlate with the development
of alloantibodies in von Willebrand’s disease. J Clin Invest 1987;79:1459–65.
[50] Ngo K, Glotz Trifard V, Koziol J, et al. Homozygous and heterozygous deletions of the von
Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl
Acad Sci U S A 1988;85:2753–7.
[51] Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and
acquired bleeding disorders. Blood 1988;72:1449–55.
[52] Rodeghiero F, Castaman G, Di Bona E, et al. Consistency of responses to repeated DDAVP
infusions in patients with von Willebrand’s disease and hemophilia A. Blood 1989;74:
1997–2000.
[53] Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von
Willebrand disease. Ann Intern Med 1991;114:563–8.
[54] Humphries JE, Siragy H. Significant hyponatremia following DDAVP administration in
a healthy adult. Am J Hematol 1993;44:12–5.
[55] Weinstein RE, Bona RD, Altman AJ, et al. Severe hyponatremia after repeated intravenous
administration of desmopressin. Am J Hematol 1989;32:258–61.
[56] Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients
with haemophilia and von Willebrand disease after repeated doses of desmopressin
(DDAVP). Br J Haematol 1992;82:87–93.
[57] Federici AB, Mazurier C, Berntorp E, et al. Biologic response to desmopressin in patients
with severe type 1 and type 2 von Willebrand disease: results of a multicenter European
study. Blood 2004;103:2032–8.
[58] Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von Willebrand factor
(VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased
VWF survival. Blood 2006;108:3344–51.
[59] Fowler WE, Berkowitz LR, Roberts HR. DDAVP for type IIB von Willebrand disease.
Blood 1989;74:1859–60.
[60] Casonato A, Sartori MT, De Marco L, et al. 1-Desamino-8-D-arginine vasopressin
(DDAVP) infusion in type IIB von Willebrand’s disease: shortening of bleeding time and
induction of a variable pseudothrombocytopenia. Thromb Haemost 1990;64:117–20.
[61] Mazurier C, Gaucher C, Jorieux S, et al. Biological effect of desmopressin in eight patients
with type 2N (Normandy) von Willebrand disease. Br J Haematol 1994;88:849–54.
[62] Rodeghiero F, Castaman G, Meyer D, et al. Replacement therapy with virus-inactivated
plasma concentrates in von Willebrand disease. Vox Sang 1992;62:193–9.
[63] Mannucci PM, Chediak J, Hanna W, et al. Treatment of von Willebrand disease with a highpurity
factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.
Blood 2002;99:450–6.
[64] Lillicrap D, Poon MC, Walker I, et al. Efficacy and safety of the factor VIII/von Willebrand
factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von
Willebrand disease. Thromb Haemost 2002;87:224–30.
[65] Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost
2002;88:378–9.
[66] Castillo R, Monteagudo J, Escolar G, et al. Hemostatic effect of normal platelet transfusion
in severe von Willebrand disease patients. Blood 1991;77:1901–5.